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Adipose-derived mesenchymal stem cells (ADMSCs) 
can self-renew and are multipotent being reportedly 
able to differentiate into multiple cell types, such as 
adipocytes, chondrocytes, osteoblasts, neuronal cells, 
and myocytes [1]. ADMSCs transplantation  has already 
 
proven effective against severe traumatic, auto-
immune, metabolic, and degenerative diseases. 
However, ADMSCs, similar to other types of me-
senchymal stem cells (MSCs), cannot expand 
infinitely in vitro [2,3]. Senescence during in vitro 
culture reduces the quality and clinical efficacy of 
ADMSCs.  


























Transplantation of adipose‐derived mesenchymal stem cells  (ADMSCs) can aid  in  the  treatment of numerous
diseases  in  animals.  However,  natural  aging  during  in  vitro  expansion  of  ADMSCs  prior  to  their  use  in
transplantation  restricts  their  beneficial  effects. Melatonin  is  reported  to  exert  biorhythm  regulation,  anti‐
oxidation, and anti‐senescence effects  in various animal and cell models. Herein, by using a senescent canine
ADMSCs (cADMSCs) cell model subjected to multiple passages in vitro, we investigated the effects of melatonin
on  ADMSCs  senescence.  We  found  that  melatonin  alleviates  endoplasmic  reticulum  stress  (ERS)  and  cell
senescence. MT1/MT2 melatonin  receptor  inhibitor,  luzindole,  diminished  the mRNA  expression  levels  and
rhythm  expression  amplitude of Bmal1  and Nrf2  genes. Nrf2  knockdown  blocked  the  stimulatory  effects  of
melatonin on endoplasmic reticulum‐associated degradation (ERAD)‐related gene expression and its inhibitory
effects on  ERS‐related  gene  expression. At  the  same  time,  the  inhibitory  effects of melatonin on  the NF‐κB
signaling pathway and senescence‐associated secretory phenotype (SASP) were blocked by Nrf2 knockdown in
cADMSCs. Melatonin pretreatment  improved the survival of cADMSCs and enhanced the beneficial effects of
cADMSCs  transplantation  in  canine  acute  liver  injury.  These  results  indicate  that  melatonin  activates  Nrf2
through  the  MT1/MT2  receptor  pathway,  stimulates  ERAD,  inhibits  NF‐κB  and  ERS,  alleviates  cADMSCs
senescence, and improves the efficacy of transplanted cADMSCs. 
www.aging‐us.com  2955  AGING 
Melatonin is an endogenous indoleamine synthesized 
from tryptophan. Melatonin is produced by the pineal 
gland from where it is released into blood system 
circulation, and regulates numerous physiological and 
endocrine functions. An important function of 
melatonin is the regulation of biological rhythms [4]. 
The decline in melatonin secretion with age suggests it 
may have anti-aging functions. Melatonin regulates 
biological rhythms by controlling the expression of 
Clock, Bmal1, Per 1-3, and Cry 1-2 [5].  
 
In addition to regulating biorhythms, melatonin can also 
play an anti-aging role due to its antioxidant effects [6]. 
Melatonin directly removes reactive oxygen species 
(ROS), and its precursors and metabolites also have 
radical scavenging activity [7,8]. In addition, melatonin 
activates numerous antioxidant genes and promotes 
Nrf2 translocation [9]. NRF2 turns on the expression of 
several antioxidant and detoxification enzymes by 
binding to the antioxidant response element (ARE) in 
their promoter regions. Oxidative stress and other factors 
can activate NRF2 dissociation from KEAP1 and its 
nuclear translocation to function as a transcription factor. 
Numerous studies have shown that NRF2 is an essential 
regulator of longevity [10]. However, activation of NRF2 
induces cellular senescence in fibroblasts [11]. This 
suggests that time-controlled activation of NRF2 may be 
critical for homeostasis in multicellular organism. 
 
Melatonin has an anti- endoplasmic reticulum stress 
(ERS) effect in liver [12], nervous system [13], and lung 
diseases [14]. In Alzheimer’s disease melatonin improves 
cognitive function by inhibiting ERS. Chronic ERS is 
closely associated with tissue aging. The unfolding 
protein response (UPR), a cellular stress response related 
to ERS, also increases dramatically with aging [15-17].  
 
The anti-senescence functions of melatonin on stem cells 
remain unclear. Several studies reported that melatonin 
reverses senescence via changes in SIRT1-dependent 
pathway, energy metabolism, epigenetic modifications, 
autophagy, circadian rhythm or other pathways [18,19]. 
However, whether replicative aging of canine ADMSCs 
(cADMSCs) is associated with ERS and whether 
melatonin has anti-ERS effects on cADMSCs remain 
unclear. In this study, we investigated the phenotype 
induced upon replicative aging of cADMSCs as well as 




Melatonin treatment relieves culture-induce 
senescence of cADMSCs 
 
Changes in cADMSCs morphology were apparent 
during prolonged in vitro culture. Staining for 
senescence-associated β-galactosidase (SA-β-gal S) 
increased between the 3rd and 11th passages. However, 
treatment with 1 μM melatonin for 7 d reduced the 
senescence phenotype of the three cADMSCs lines 
tested, as indicated by significantly reduced staining in 
cADMSCs at passage 11 treated with 1 μM compared to 
0 μM melatonin (Fig. 1A). Therefore, 1 μM was chosen 
as the optimal concentration of melatonin to be used in 
subsequent experiments (Supplementary Fig. 1).  
 
The osteogenic and chondrogenic differentiation 
potential of cADMSCs decreased between the 3rd and 
11th passages, but less so in melatonin-treated 
cADMSCs (Fig. 1B). Similarly, staining for γH2AX 
increased while telomerase activity and relative 
telomere length T/S ratio decreased between the 3rd and 
11th passages, and these effects were attenuated by 
melatonin treatment (Fig. 1C-E). Moreover, transcript 
levels of SASP (Ccl2, Tnf-a, Vegf, IL6 and Cxcl8) and 
ERS (Grp78, Chop, Xbp1, Atf4 and Atf6) markers as 
well as protein levels of ERS (p-PERK and p-IRE1), 
SASP (IL6 and TNF-a), and senescent (P16 and P21) 
markers all increased in cADMSCs between the 3rd and 
11th passages, and these effects were attenuated by 
melatonin treatment (Fig. 1F- H). 
 
ERS regulates senesce of cADMSCs 
 
To explore the relationship between the anti-senescent 
and ERS reducing effects of melatonin, cADMSCs at 
passage 11 were treated with either ERS inhibitor 4-
PBA or ERS activator tunicamycin (TM). 4-PBA 
relieved the senescent phenotype of cADMSCs. 
Specifically, treatment with 0.25 mM 4-PBA for 12 h 
reduced the expression of ERS markers (Grp78, Chop, 
Xbp1, Atf4 and Atf6) (Fig. 2A).  
 
In addition, 4-PBA-treated cADMSCs showed a higher 
nucleus-to-cytoplasm ratio (Fig. 2B), lower SA-β-gal S 
staining (Fig. 2C), shorter population doubling time 
(Fig. 2D), and lower expression of SASP (Cxcl8, Mmp3 
and Tnf-a) markers (Fig. 2G) than non-treated cells. 4-
PBA treatment also decreased the protein levels of ERS 
markers including p-PERK and p-IRE1, the SASP 
marker IL6, and the senescent markers P16 and P21 
(Fig. 2H). 
 
To confirm the association between reduced senescence 
and reduced levels of ERS markers, cADMSCs were 
treated with ERS activator TM (30 ng/mL for 12 h). TM 
increased the expression of ERS markers (Grp78, Chop, 
Xbp1, Atf4 and Atf6) (Fig. 2A), reduced the nucleus-to-
cytoplasm ratio (Fig. 2B), increased SA-β-gal S staining 
(Fig. 2C), increased the population doubling time (Fig. 
2D), reduced telomerase activity (Fig. 2E) and the 
relative telomere length T/S ratio (Fig. 2F), and decreas- 










































ed the mRNA levels of SASP markers (Il6, Cxcl8, Tnf-a 
and Mmp3) (Fig. 2G) and protein levels of ERS (p-
PERK and p-IRE1), SASP (IL6) and senescent (P16 
and P21) markers (Fig. 2H). 
 
Melatonin activated circadian clock genes and 
NRF2, and decreased ERS through MT1/MT2 
 
Melatonin influences the body’s circadian clock as well 
as MSCs activity in vitro by regulating clock genes 
[20,21]. In addition, primary cell cultures can gradually 
lose their circadian rhythmicity. To further elucidate the 
anti-aging and circadian-regulatory effects of melatonin, 
we determined the expression of clock genes in primary 










































tude circadian fluctuations of clock genes (Per2 and 
Bmal1) than cells at passage 11 (Fig. 3A-B).  
 
NRF2 has been reported to be an important redox-
sensitive and anti-aging transcription factor [22], and to 
be transcriptionally activated by clock genes via the E-
box element [23]. Circadian fluctuations of Nrf2 in 
passage 0 cells were no longer detectable at passage11 
(Fig. 3C). Similarly, circadian fluctuations of the ERS 
gene Grp78 in primary cADMSCs were lost during in 
vitro culture (Fig. 3G). Interestingly, melatonin treat-
ment was able to restore fluctuations in the clock genes, 
Bmal1 and Nrf2, in 11th passage cADMSCs (Fig. 3E-
F), and decreased Grp78 expression (Fig. 3H). In 
addition, melatonin treatment for 12 h increased protein 
Figure 1. Melatonin attenuates ERS and SASP in cADMSCs. (A) SA‐β‐gal S of cADMSCs. (P3, 3rd passage, P11, 11th
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levels of MT1/MT2 (Fig. 3D). Finally, the stimulatory 
effects of melatonin on gene expression fluctuations 
were inhibited by addition of the melatonin receptor 
inhibitor luzindole (1μM) (Fig. 3E-F). These results 
indicate that melatonin may activate rhythmic genes 
(e.g., NRF2) and inhibit ERS genes in cADMSCs 
through a receptor-mediated mechanism.  
 
Melatonin attenuated senescence of cADMSCs by 
activating NRF2 
 
Melatonin treatment for 12h increased the expression of 
Nrf2 and its target genes, namely, Nqo1, Ho-1, and Gclc 
in 11th passage cADMSCs (Fig. 4A). Dual-luciferase 
assay indicated that melatonin and MT1/MT2 activator 
ramelteon (10 nM) induced the transcriptional activity 
of NRF2, whereas luzindole (1μM) treatment inhibited 







































had a more intense nuclear staining in melatonin-treated 
and melatonin receptor agonist ramelteon-treated 
cADMSCs than in control and luzindole-treated 
cADMSCs. In contrast, cytoplasmic staining of NRF2 
was more intense in control and luzindole-treated 
cADMSCs than in melatonin-treated and ramelteon-
treated cADMSCs (Fig. 4C). Western blotting showed 
that NRF2 protein was increased in melatonin-treated 
cells or cells treated with a combination of melatonin 
and ramelteon (Fig. 4D). We then knocked down Nrf2 
in passage 3 cADMSCs via shRNA vector. This stra-
tegy resulted in 88% and 68% reduction in Nrf2 levels 
in two cell lines (shNrf2-1 and shNrf2-2), respectively 
(Fig. 4E), and led to an increase in the population 
doubling time (Fig. 4F) and SA-β-gal S staining (Fig. 
4G) of melatonin treated cADMSCs. Thus, NRF2 





























































































Melatonin reduced ERS by activating NRF2-
endoplasmic reticulum-associated degradation 
(ERAD) 
 
The reduction in ERS by melatonin through activation 
of ERAD has been reported in several studies [24-26]. 
Consistent with this, the ERAD markers Hrd1, Vcp, and 
Os9 increased remarkably after treatment of cADMSCs 
with melatonin for 12h, while Hrd1 was inhibited by 
luzindole (Fig. 5A). To test whether the ERAD-














































luated the expression of ERAD markers at 12h after 
treatment with the NRF2 activator oltipraz (15 μM). 
This resulted in the increased expression of ERAD 
marker to levels similar to those induced by melatonin 
treatment (Fig. 5A), a result that was confirmed by 
Western blot analyses (Fig. 5B). However, melatonin 
did not increase the expression of ERAD (Hrd1, Vcp, 
and Os9) (Fig. 5C) and ERS (Xbp1, Atf4, Atf6, and 
Grp78) markers (Fig. 5D) in shNRF2-cADMSCs. 
Levels of p-IRE1 and IL6 protein increased in 
shNRF2-cADMSCs compared with those in melato-
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nin-treated cADMSCs (Fig. 5E). The ERS-reducing 
effect of melatonin treatment was blocked by 






















































μM) and NMS-873 (0.5 μM) (Fig. 5F-G). These 

























































luzindole+melatonin‐treated P11 cADMSCs.  (C)  Immunohistochemistry of NRF2  in control, melatonin‐,  ramelteon+melatonin‐
and  luzindole+melatonin‐treated P11 cADMSCs. bar = 200 μm  (D) Western blot quantification of nucleoprotein and cytosolic




















































































































Figure 5. Melatonin  reduces ERS  through activating NRF2 and ERAD and  inhibiting NF‐κB and SASP.  (A) Relative  transcript
levels  of  ERAD‐related  genes  in  P11  control,  melatonin‐,  luzindole+melatonin‐  and  oltipraz‐treated  cADMSCs.  (B)  Western  blot
quantification  of  ERAD‐related  protein  in  control,  melatonin‐,  luzindole+melatonin‐  and  oltipraz‐treated  P11  cADMSCs.  (C)  Relative
transcript  levels of ERAD‐related genes  in negative control, mock, shRNA vector, melatonin‐treated, shNrf2‐1, and shNrf2‐2 P3 cADMSCs.
(D) Relative  transcript  levels of ERS‐related genes  in negative control, mock, vector, melatonin‐treated mock, shNrf2‐1, and shNrf2‐2 P3
cADMSCs.  (E) Western blot and multiple quantifications of ERS‐related protein  (NRF2)  in  the negative control, mock, vector, melatonin‐
treated  mock,  shNrf2‐1,  and  shNrf2‐2  P3  cADMSCs.  (F)  Relative  transcript  levels    of  ERS‐related  genes  in  control,  melatonin‐,  MG‐
132+melatonin‐  and  NMS‐873+melatonin‐treated  P11  cADMSCs.  (G)  Western  blot  quantification  of  ERS‐related  genes  in  control,
melatonin‐, MG‐132+melatonin‐ and NMS‐873+melatonin‐treated P11 cADMSCs. (H) Relative transcript  levels of SASP‐related genes (P50
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Melatonin reduced SASP by activating NRF2 and 
inhibiting NF-κB 
 
SASP is deemed to be a trigger of ERS in aging cells 
[27]. We found that melatonin reduced the expression 
levels of SASP and ERS markers at 12h after treatment 
in 11th passage cADMSCs (Fig. 1F-H). The NF-κB 
pathway is well-known to regulate SASP, so we tested 
the effect of melatonin treatment on NF-κB. Melatonin 
or oltipraz treatment for 12h decreased the transcript 
levels of P65 and P50 (Fig. 5H) and the protein levels of 
IKK, p-P65, and P65 (Fig. 5I). However, luzindole 
blocked the inhibitory effects of melatonin on NF-κB, 
and when compared to melatonin alone, luzindole in 
combination with melatonin treatment increased 
transcript levels of P65, P50, IL6, Tnf-a, Ccl2, and 
Cxcl8 (Fig. 5H) and protein levels of IKK, p-P65, and 
P65 (Fig. 5I).  
 
In addition, dual-luciferase assay showed that melatonin 
reduced the transcriptional activity of P65 (Fig. 5J). To 
confirm the NF-κB-reducing effect of NRF2, we 
determined the expression levels of P65, P50, IL6, and 
Tnf-a in shNRF2-cADMSCs, and showed that these 
increased significantly compared to 3rd passage 
cADMSCs (Fig. 5K). The protein level of P65 and IL6 
also increased in shNRF2-cADMSCs (Fig. 5E).  
 
Melatonin pretreatment increased the clinical 
efficacy of cADMSCs  
 
cADMSCs have been reported to aid regeneration of 
injured liver [28], however, the therapeutic properties of 
cADMSCs may be reduced by long-term culture in vitro 
[29]. To explore the effects of melatonin on the 
therapeutic potential of cADMSCs, we transplanted 
cADMSCs, previously treated or not with melatonin, 
into CCl4-treated dogs, a common model of induced 
acute liver injury. cADMSCs (1× 107 per 10 mL) were 
administered by intravenous injection to dogs 10 h after 
administration of CCl4. cADMSCs at passage 9 rather 
than passage 11 were used as we reasoned that higher 
cell viability would resulted in higher therapeutic 
effects. Food and water intake analyses showed that 
cADMSC injection accelerated recovery relative to 
CCL4-induced acute liver injury dogs. Average food 
intake of melatonin-pretreated cADMSCs injection 
group was significantly higher than CCL4 injury group 
from the 1st day after cADMSCs transplantation (Fig. 
6A-B). Hepatic tissue was collected on the 5th day after 
cell transplantation. The liver index (liver/body weight) 
of the CCl4 group was significantly higher than that of 
the control group, and this increase was prevented by 
injection with melatonin-pretreated cADMSCs (Fig. 
6C). Blood serum was collected 1 day before CCL4 
injury, 10 h after CCl4 injection and on the 5th day after 
cell transplantation. Aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) significantly 
increased, whereas Albumin (ALB) decreased after 
CCl4 injection. Higher recovery rates were observed in 
dogs injected with melatonin-pretreated cADMSCs than 
with untreated cADMSCs. (Fig. 6D-F). PKH26-positive 
cells were found in frozen liver sections of cADMSCs-
injected dogs. Red fluorescence intensity was higher in 
tissues from dogs injected with melatonin-pretreated 
cADMSCs than with untreated cADMSCs (Fig. 6G). 
HE staining of liver sections showed extensive histo-
pathological changes induced by CCl4, characterized by 
hepatic lobule impairment, severe hepatocyte de-
generation, necrosis, fatty changes, inflammatory cell 
infiltration, and congestion (Fig. 6H). Histopathological 
scores for acute liver injury are shown in 
Supplementary Table 1. Five different visual fields from 
2 donors’ liver sections were analyzed in each group. 
Tissues from dogs transplanted with melatonin-
pretreated cADMSCs had a significantly smaller score 
than those from dogs transplanted with untreated 
cADMSCs (Fig. 6I). Expression of ERS-related genes 
Grp78, Atf4, Atf6, and Xbp1 was increased by CCl4 
treatment, and this effect was attenuated in animals 
transplanted with melatonin-pretreated cADMSCs 




The therapeutic value of ADMSCs has been shown in 
numerous studies [30]. Properties such as easy sourcing 
free of ethical concerns and lack of tumorigenicity 
render ADMSCs an ideal cell source for regenerative 
therapies. However, ADMSC senescence during in vitro 
expansion prior to transplantation reduces the survival 
rate and therapeutic efficacy of these cells. Cell 
morphology, proliferation rate, differentiation potential, 
and gene expression change during repeated passages of 
ADMSCs [2]. The SASP of senescence cells even 
contributes to systemic dysfunction in age-related 
diseases [31]. In this study, the expression levels of 
SASP- and ERS-related transcripts and proteins in-
creased in senescent cADMSCs. Reports on the 
relationship between cell senescence and ERS are 
scarce and often disagree [15-17, 32]. Also, the ERS 
inhibitor 4-PBA attenuates aging of bone marrow-
derived MSCs in patients with systemic lupus erythe-
matosus [33]. 
 
Melatonin has anti-aging actions in a number of animal 
and cell models [34]. For example, melatonin attenuated 
a reduction in telomerase activity in the retina of 
patients with age-related macular degeneration [35], as 
well as senescence of bone marrow MSCs [36]. We 
showed that the inhibitory effects of melatonin on cell 
senescence involved effects on ERS.  Melatonin 
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mitigates memory deficits [37] and Alzheimer-like 























































shows ERS suppressive effects in numerous other 
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The mechanisms involved in these effects are unclear. 
NRF2 is a transcription factor that regulates various 
anti-oxidation and detoxification enzymes. NRF2 has 
been reported to prolong the life span of mice or 
Caenorhabditis elegans [22, 39]. Melatonin can activate 
NRF2 by inhibiting its ubiquitination [40] and 
promoting its transportation to the nucleus [41]. Herein, 
we showed a link between the activation of NRF2 by 
melatonin and circadian clock gene activity. Melatonin 
not only alters the transmission effects of biological 
clock, but also acts as a zeitgeber which stabilizes, 
strengthens, and coordinates biological rhythmicity. 
Melatonin acts on the MT1/MT2 receptor of the 
suprachiasmatic nucleus, pituitary, brown fat, pineal 
gland, and other tissue cells and regulates the rhythmic 
expression of Clock, Bmal, Per, and Cry [20]. A 
previous study showed that Bmal1 and Clock in 
broncho alveolar epithelial cells can bind to the E-box 
(5'-CACGTG-3') of target genes including Nrf2 and 
regulate the transcription of numerous rhythmic genes 
[23]. A similar E-box sequence (5’-GACGTG-3’) exists 
in the promoter region of the Nrf2 gene in canines. We 
found that, despite melatonin increasing Bmal1 and 
Nrf2 fluctuations in cADMSCs at passage 11, ex-
pression of these genes was not restored to the levels 
observed in primary passage of cADMSCs. This may be 
due to melatonin treatments were transient rather than 
involving a slow and prolonged increase as occurs in 
vivo. We found that melatonin also regulates the 
rhythmic expression of the ERS-related gene Grp78. 
However, further studies on the melatonin-induced 
rhythm expression of ERS-related  genes  are  necessary. 
ERAD promotes the degradation of misfolded proteins, 
prevents protein aggregation in the endoplasmic 
reticulum, and protects cells against chronic ERS. In the 
current study, melatonin had an anti-ERS effect upon 
activation of the ERAD pathway in cADMSCs. Recent 
reports have shown that melatonin reduces ERS in 
corneal fibroblasts by activating ERAD [42]. Several 
studies have shown that NRF2 is a master regulator of 
ERAD-related genes [43]. The activity of protease 
increased and aging was effectively alleviated in NRF2 
activator-treated human skin fibroblasts [44]. Herein, 
NRF2 and ERAD activation were found to be 
indispensable for the anti-ERS action of melatonin-
treated cADMSCs. 
 
NF-κB is an important regulation of the expression of 
SASP-related genes in senescent cells [45]. SASP is a 
major cause of cell UPR in senescent cells, because 
increased secretion of SASP-related factors leads to the 
accumulation of excessive unfolded proteins in the 
endoplasmic reticulum [27]. This phenomenon has been 
confirmed in chemotherapeutic drug-induced senes-
cence. Studies have shown that UPR reactions occurs 
only in senescent cells with SASP [46]. Oxidative stress 
activates NF-κB [47]. As a major regulator of 
antioxidant genes, Nrf2 and its activator can also inhibit 
the NF-κB pathway [48]. However, the mechanisms by 
which Nrf2 and NF-κB interact require further study. 
 
The mechanisms by which cADMSC injection is 
beneficial to animals with liver injury is unclear. Some 
studies suggested that MSCs can differentiate into 
hepatocytes thereby reconstructing damaged liver tissue 
[49]. Other studies demonstrated that MSCs secrete 
growth factors and other substances that promote the 
self-reconstruction of liver tissues [50]. Yet others 
showed that MSCs act by reducing inflammatory 
responses [51]. In our study, melatonin pretreatment 
improved the survival of cADMSCs and decreased ERS 
in the acute liver injury model. These results suggest 
that melatonin treatment inhibited senesce of cADMSCs 
and improved their beneficial actions after trans-
plantation. 
 
Overall, our results show that melatonin had an anti-
senescent effect in cADMSCs by inhibiting ERS 
through activation of rhythmic expression of NRF2, 
activating the ERAD pathway, and inhibiting the NF-κB 
pathway (Fig. 6K). Melatonin treatment improved the 
survival rate of cADMSCs in the acute liver injury 
model.   
 
MATERIALS AND METHODS 
 
Cell isolation, identification, and culture 
 
cADMSCs [52] were isolated by collagenase type I 
(Roche Diagnostics, Switzerland) digestion of 
abdominal subcutaneous adipose tissue collected from 
three 1 year old female cross-bred dogs. cADMSCs 
were cultured in α-MEM (Invitrogen, Carlsbad, CA) 
supplemented with 10% FBS (HyClone, UT, USA), 2 
mM L-glutamine, and 1% non-essential amino acids 
(Invitrogen) in a humid atmosphere of 5% CO2 at 37 
°C. Cells were passaged every 2 days with trypsin–
EDTA (Invitrogen). The identity of ADMSCs was 
confirmed by flow cytometry and differentiation into 
adipogenic lineage and osteogenic lineage, as in 
previous studies [52]. Melatonin (M5250; Sigma, 
Milan, Italy) was dissolved in dimethyl sulfoxide 
(DMSO; D5879; Sigma) at a concentration of 10 mM. 
DMSO only was used as control cells. 
  
Osteogenic and chondrogenic differentiation of 
cAMSCs in vitro  
 
About 2×104 cells were seeded into 12-well plates in 
αMEM with 10% FBS, 100 nmol/L dexamethasone, 30 
μg/mL ascorbic acid, and 10 mmol/L β-
glycerophosphate (Sigma-Aldrich, St. Louis, MO, 
www.aging‐us.com  2964  AGING 
USA) for 14 days. Osteogenic differentiation was 
assessed by alizarin red staining. To induce chondro-
genesis, cADMSCs were grown in αMEM with 10% 
FBS, 40 ng/mL dexamethasone, 50 μg/mL ascorbic 
acid, 50 μg/mL L-proline, 1 mM sodium pyruvate (all 
Sigma-Aldrich), insulin–transferrin–selenium X (Gibco, 
Carlsbad, California, USA), and 10 ng/mL transforming 
growth factor-β3 (PeproTech, Rocky Hill, NJ, USA) for 
14 days. Chondrogenesis was assessed with alcian blue 
staining. 
 
Senescence associated β-galactosidase staining 
 
Cells were stained with β-galactosidase staining kit 
(Beyotime, Shanghai, China). cADMSCs were fixed for 
15 min. The cells were washed 3 times with PBS 
followed by staining with the solution A, B, C and X-
gel mixed liquor for 10 h at 37 °C.  
 
Population doubling time (PDT)  
 
The population doubling time (PDT) of cADMSCs was 
estimated according to the formula PDT = [log 2/(log 
Nt−logN0)]× t. N0 indicates the number of seeded cells, 
Nt indicates the number of cells after t h of culturing, 




Cells were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) at room temperature (RT) for 10 
min. Nuclear staining was performed with 1 μg/mL 
Hoechst 33342 (Sigma Aldrich). Fluorescence images 
was obtained with Evos f1 fluorescence microscope 
(AMG, USA) and analyzed using Image J software 
(National Institutes of Health, USA). 
 
Telomerase activity assay 
 
Telomerase activity in cell extracts was measured using 
the TRAPeze RT Telomerase Detection Kit (S7710, 
Millipore, USA). The amount of extended telomerase 
substrate (amoles) produced per mg of protein per 
minute for each sample cell extract was obtained as per 
manufactuer’s instructions and used as Y-axis when 
drawing bar charts. 
 
Telomere length assays 
 
cADMSCs were extracted using a DNA Isolation Kit 
(Tiangen, China) according to the manufacturer’s 
instructions. The ratio of telomere repeat copy number 
to single gene copy number (T/S) was determined using 
QRT-PCR in the CFX96 Real-Time PCR system. QRT-
PCR procedures were described as follows: pre-
denaturation at 94 °C for 10 min, followed by 39 cycles 
for 15 s at 94 °C, and annealing for 1 min at 56 °C. The 
telomere reaction mixture consisted of 1× Quantitect 
Sybr Green Master Mix, 2.5 mM of DTT, 100 nM of 
Tel-F primer (CGGTTTGTTTGGGTTTGGGTTTGGG 
TTTGGGTTTGGGTT), and 900 nM of Tel-R primer 
(GGCTTGCCTTACCCTTACCCTTACCCTTACCCT
TACCCT). 36B4 was used as the loading control, with 
36B4-F primer (ACTGGTCTAGGACCCGAGAAG) 
and 36B4-R primer (TCAATGGTGCCTCTGGAGATT). 
DNA quantitation was performed using Thermo 
NanoDrop 2000 (Thermo Scientific) and double 
dilution of DNA in the control sample. Comparative CT 
values from QRT-PCR were used to draw the standard 
curve. The T/S ratio for each sample was calculated by 
dividing of the average 36B4 ngDNA value by the 
average telomere ngDNA. 
 
Synchronization of cADMSCs 
 
When cADMSCs reached 50% confluence they were 
treated with α-MEM medium containing 0.5% FBS for 
24 h. The medium was then changed to α-MEM 
medium containing 50 % FBS for 1h. cADMSCs were 
then cultured with α-MEM medium containing 0.5 % 
FBS with or without melatonin during which samples 
were collected every 4 hours and the relative expression 
of genes was determined. 
 
Quantitative real-time PCR analysis 
 
The total RNA of cADMSCs was extracted using Trizol 
reagent (Takara, Japan) according to the manufacturer’s 
instructions. Reverse Transcriptase Reagent kit (Thermo 
Scientific) was used according to the manufacturer’s 
instructions. Quantitative real-time PCR (QPCR) was 
carried out with the CFX96 Real-Time PCR system as 
follows: pre-denaturation at 94 °C for 5 min, following 
39 cycles for 30 s at 94 °C, annealing for 30 s at 58 °C 
and 30 s at 70 °C for extending. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as the 
loading control. Comparative CT-values from QPCR 
were used to measure relative gene expression. Primers 
are listed in Supplementary Table 2. 
 
Construction of the ShNrf2 interference vector 
 
The plasmid pSIH-H1-CopGFP-shRNA was used. 
Target sequences were designed by BLOCK-iT™ 
RNAi Designer(Thermo Fisher) and are listed in 




Plasmids pGL3-ARE-luc were used to analyze the 
NRF2 activity. pGL4-NF-κB-RE-luc (Promega, USA) 
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was used to analyze the NF-κB activity. The pRL-TK 
Renilla luciferase (Promega, USA) plasmid was used to 
control for transfection efficiency. The activities of 
Firefy and Renilla luciferase were determined using the 
dual-luciferase reporter assay system (Promega, USA) 
according to manufacturer instructions. Assays were 
independently conducted at least in triplicate. The data 
presented show relative Firefy luciferase activity 




Cells were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) at room temperature (RT) for 10 
min, washed three times with PBS, and then 
permeabilized for 15 min with 0.1% Triton-X 100 
(Sigma-Aldrich, St. Louis, MO) in PBS at RT. Cells 
were blocked with PBS supplemented with 4% bovine 
serum albumin for 30 min and incubated with primary 
antibodies against NRF2 (1:200, D121053, Sangon 
Biotech, China), and γH2AX (1:200, sc-517348, Santa 
Cruz, USA) at 4 °C for 16 h. After washing with PBS 
three times, cells were incubated with secondary 
antibodies for 1 h at 37 °C in the dark. Following 
another three washing steps in PBS, nuclear 
counterstaining was performed with 1 μg/mL Hoechst 
33342 (Sigma Aldrich). Fluorescence images were 





Total cell extracts were prepared in 1× sodium dodecyl 
sulfate- polyacrylamide gel electrophoresis (SDS-
PAGE) sample loading buffer. Cell fractions were 
extracted with nuclear and cytoplasm protein extraction 
kit (Wanleibio, China). Cell proteins were resolved by 
SDS-PAGE, transferred to a polyvinylidene difluoride 
membrane, and probed with GAPDH (1:1000, BM3876, 
Bosterbio, USA), p-PERK, p-IRE1, ATF4, P16 (1:500, 
bs-3330R, bs-16698R, bs-1531R, bs-20656R, Bioss, 
China), H3, NRF2 (1:500, D153567, D121053, Sangon 
Biotech, China), and TNF-α, IL-6, P21, MT1, MT2, 
HRD1, VCP, P65, p-P65, IKK (1:200, sc-52746, sc-
32296, sc-136020, sc-13180, sc-13177, sc-293484, sc-
136273, sc-514451, sc-166748, sc-7606, Santa Cruz, 
USA). Secondary anti-rabbit, anti-mouse antibodies  
(1:1000, BM2004, BA1001, Bosterbio, USA) 
conjugated with horseradish peroxidase were used. 
Detection was performed using a Thermo Scientific 
Pierce enhanced chemiluminescence western blotting 
substrate (Thermo Scientific). Results were analyzed by 
Tanon-410 automatic gel imaging system (Shanghai 
Tianneng Corporation, China). 
 
Acute hepatic injury model 
 
All the animals were used according to Chinese 
Laboratory Animal Guidelines and after approval by the 
committee of Shaanxi Centre of Stem Cells Engineering 
& Technology, Northwest A&F University. Eight 1 
year old female small cross-bred dogs with body weight 
5 ± 0.1 kg were used. All animals were kept under 
constant temperature (25 ± 2°C) and light (12:12 h 
light:dark cycle) and granted free access to standard dry 
chow and water. The dogs were randomly assigned to 
four experimental groups (n = 2): control (intra-
peritoneal injection of 0.54 mL/kg olive oil,); CCl4 
(intraperitoneal injection of 40% CCl4 dissolved in 
0.9 mL/kg olive oil,); cADMSCs (intravenous injection 
of 100 million PKH26 (Sigma, USA)-labeled 
cADMSCs in 10 mL phosphate buffer saline (PBS) at 
10 h after CCl4); and cADMSCs–melatonin (cADMSCs 
were pretreated with 1μΜ melatonin for 7d before 
injection to dogs). The liver index (liver weight 
(g)/body weight (g) × 100) was calculated 5 days after 
cADMSCs transplantation. Blood biochemistry was 
performed before and 10 h after CCl4 injection, and 5 
days after cADMSCs transplantation. Aspartate amino-
transferase (AST), alanine aminotransferase (ALT) and 
Albumin (ALB) activities in serum were analyzed by 
FUJI DRI-CHEM NX500iVC biochemical analyzer 
(FUJI Film, Japan). HE staining of frozen and paraffin 
sections was conducted at 5 days after cADMSCs 
transplantation. Supplementary Table 1 shows the 
histopathological score for acute liver injury. The 
histopathological score of 5 different visual fields from 




One-way ANOVA was used followed by Newman–
Keuls multiple range tests whenever main effects were 
significant. Student's t-test was used when comparing 
two means. All data are presented as mean ±SD, and 
statistical significance is shown as follows: *p < 0.05; 
**p < 0.01; ***p < 0.001. All data were analyzed using 
GraphPad Prism software (La Jolla, CA, USA) and 




We thank Dr. Russel J. Reiter, Dr. Kuldip Sidh’and Dr. 
Christian DANI’s for helpful review and comments on 
the manuscript. 
 
CONFLICTS OF INTEREST 
 
The authors declare that they have no conflicts of 
interest with the contents of this article. 
 
www.aging‐us.com  2966  AGING 
FUNDING 
 
This work was supported by grants from the Program of 
National Natural Science Foundation of China 
(31572399), The National Key Research and 
Development Program of China, Stem Cell and 





derived  stromal  cells‐‐basic  and  clinical  implications 
for  novel  cell‐based  therapies.  Stem  Cells.  2007; 
25:818–27.  https://doi.org/10.1634/stemcells.2006‐
0589 
2.   Hu  C,  Li  L.  Preconditioning  influences mesenchymal 

















Xu  B.  Mitochondria:  central  organelles  for 
melatonin’s  antioxidant  and  anti‐aging  actions. 
Molecules. 2018; 23:509.  
  https://doi.org/10.3390/molecules23020509 
7.   Reiter  RJ,  Mayo  JC,  Tan  DX,  Sainz  RM,  Alatorre‐
Jimenez M, Qin L. Melatonin as an antioxidant: under 
promises  but  over  delivers.  J  Pineal  Res.  2016; 
61:253–78. https://doi.org/10.1111/jpi.12360 




9.   Manchester  LC,  Coto‐Montes  A,  Boga  JA,  Andersen 
LP,  Zhou  Z,  Galano  A,  Vriend  J,  Tan  DX,  Reiter  RJ. 
Melatonin:  an  ancient molecule  that makes  oxygen 
metabolically  tolerable.  J  Pineal  Res.  2015;  59:403–
19. https://doi.org/10.1111/jpi.12267 
10.  Bruns DR, Drake JC, Biela LM, Peelor FF 3rd, Miller BF,  
Hamilton  KL.  Nrf2  signaling  and  the  slowed  aging 
phenotype:  evidence  from  long‐lived  models.  Oxid 
Med Cell Longev. 2015; 2015:732596.  
  https://doi.org/10.1155/2015/732596 
11.  Hiebert  P,  Wietecha  MS,  Cangkrama  M,  Haertel  E, 
Mavrogonatou E,  Stumpe M,  Steenbock H, Grossi  S, 
Beer HD, Angel P, Brinckmann J, Kletsas D, Dengjel J, 
Werner  S.  Nrf2‐mediated  fibroblast  reprogramming 
drives  cellular  senescence  by  targeting  the 
matrisome. Dev Cell. 2018; 46:145–161.e10.  
  https://doi.org/10.1016/j.devcel.2018.06.012 
12.  Zaouali  MA,  Boncompagni  E,  Reiter  RJ,  Bejaoui  M, 
Freitas  I,  Pantazi  E,  Folch‐Puy  E,  Abdennebi  HB, 
Garcia‐Gil FA, Roselló‐Catafau J. AMPK involvement in 




13.  Carloni  S,  Albertini  MC,  Galluzzi  L,  Buonocore  G, 
Proietti  F,  Balduini  W.  Melatonin  reduces 
endoplasmic reticulum stress and preserves sirtuin 1 
expression  in  neuronal  cells  of  newborn  rats  after 
hypoxia‐ischemia.  J  Pineal  Res.  2014;  57:192–99. 
https://doi.org/10.1111/jpi.12156 
14.  Zhao H, Wu QQ, Cao LF, Qing HY, Zhang C, Chen YH, 
Wang  H,  Liu  RY,  Xu  DX.  Melatonin  inhibits 
endoplasmic  reticulum  stress  and  epithelial‐mesen‐
chymal  transition  during  bleomycin‐induced  pulmo‐
nary  fibrosis  in  mice.  PLoS  One.  2014;  9:e97266. 
https://doi.org/10.1371/journal.pone.0097266 
15.  Baehr  LM, West  DW, Marcotte  G, Marshall  AG,  De 
Sousa  LG, Baar  K, Bodine  SC. Age‐related deficits  in 
skeletal  muscle  recovery  following  disuse  are 
associated  with  neuromuscular  junction  instability 
and ER  stress, not  impaired protein  synthesis. Aging 
(Albany NY). 2016; 8:127–46.  
  https://doi.org/10.18632/aging.100879 
16.  Chalil  S,  Jaspers  RT,  Manders  RJ,  Klein‐Nulend  J, 
Bakker  AD,  Deldicque  L.  Increased  endoplasmic 
reticulum  stress  in  mouse  osteocytes  with  aging 




Elevated  endoplasmic  reticulum  stress  response 
contributes to adipose tissue inflammation in aging. J 




O2  ‐induced premature  senescence  in mesenchymal 
stem cells via the SIRT1‐dependent pathway. J Pineal  




P,  Govitrapong  P.  Melatonin  regulates  aging  and 
neurodegeneration  through  energy  metabolism, 
epigenetics,  autophagy  and  circadian  rhythm  path‐
ways. Int J Mol Sci. 2014; 15:16848–84.  
  https://doi.org/10.3390/ijms150916848 
20.  Torres‐Farfan  C,  Rocco  V,  Monsó  C,  Valenzuela  FJ, 
Campino  C,  Germain  A,  Torrealba  F,  Valenzuela  GJ, 
Seron‐Ferre M. Maternal melatonin  effects on  clock 
gene  expression  in  a  nonhuman  primate  fetus. 
Endocrinology. 2006; 147:4618–26.  
  https://doi.org/10.1210/en.2006‐0628 
21.  Brodskiĭ  VI,  Vasil’ev  AV,  Terskikh  VV,  Zvezdina  ND, 
Fateeva VI, Mal’chenko LA, Kiseleva EV, Bueverova EI. 
Mesenchymal stromal cells synchronize the rhythm of 
protein  synthesis  under  the  effect  of  an  exogenous 
signal. Ontogenez. 2012; 43:229–32. 
22.  Singh SP, Niemczyk M, Saini D, Sadovov V, Zimniak L, 




23.  Pekovic‐Vaughan  V,  Gibbs  J,  Yoshitane  H,  Yang  N, 
Pathiranage D, Guo B, Sagami A, Taguchi K, Bechtold 
D, Loudon A, Yamamoto M, Chan J, van der Horst GT, 
et  al.  The  circadian  clock  regulates  rhythmic 
activation  of  the  NRF2/glutathione‐mediated  anti‐




Z,  Shen  W,  Reiter  RJ,  Hua  J,  Peng  S.  Melatonin 
attenuates  detrimental  effects  of  diabetes  on  the 




Hua  J,  Peng  S. Melatonin  Relieves  busulfan‐induced 
spermatogonial  stem  cell  apoptosis  of mouse  testis 




Y,  Liu  W,  Zhao  B,  Peng  S,  Li  G,  Hua  J.  Melatonin 
ameliorates  busulfan‐induced  spermatogonial  stem 




response and  cellular  senescence.  A  review  in  the  





Cai  Z,  Liu  X,  Liu  J. Adipose  tissue‐derived  stem  cells 
promote  the  reversion  of  non‐alcoholic  fatty  liver 





al.  Long‐term  cultured  mesenchymal  stem  cells 
frequently  develop  genomic  mutations  but  do  not 





Seifalian  AM, Whitaker  IS.  The  regenerative  role  of 
adipose‐derived  stem  cells  (ADSC)  in  plastic  and 
reconstructive  surgery.  Int Wound  J.  2017;  14:112–
24. https://doi.org/10.1111/iwj.12569 
31.  Xu M,  Pirtskhalava  T,  Farr  JN, Weigand  BM,  Palmer 
AK, Weivoda MM,  Inman CL, Ogrodnik MB, Hachfeld 
CM, Fraser DG, Onken JL, Johnson KO, Verzosa GC, et 
al. Senolytics  improve physical  function and  increase 
lifespan  in  old  age.  Nat  Med.  2018;  24:1246–56. 
https://doi.org/10.1038/s41591‐018‐0092‐9 
32.  Kannan S, Dawany N, Kurupati R, Showe LC, Ertl HC. 





progress  of  senescence  of  bone  marrow‐derived 














al.  Melatonin  protects  bone  marrow  mesenchymal 
stem  cells  against  iron  overload‐induced  aberrant 
www.aging‐us.com  2968  AGING 
differentiation  and  senescence.  J  Pineal  Res.  2017; 
63:e12422. https://doi.org/10.1111/jpi.12422 
37.  Shi C, Zeng J, Li Z, Chen Q, Hang W, Xia L, Wu Y, Chen 
J,  Shi  A.  Melatonin  mitigates  kainic  acid‐induced 
neuronal  tau  hyperphosphorylation  and  memory 




Wang  JZ.  Constant  illumination  induces  Alzheimer‐
like  damages  with  endoplasmic  reticulum 
involvement  and  the  protection  of  melatonin.  J 
Alzheimers Dis. 2009; 16:287–300.  
  https://doi.org/10.3233/JAD‐2009‐0949 
39.  An  JH,  Vranas  K,  Lucke  M,  Inoue  H,  Hisamoto  N, 
Matsumoto  K,  Blackwell  TK.  Regulation  of  the 
Caenorhabditis  elegans  oxidative  stress  defense 
protein  SKN‐1  by  glycogen  synthase  kinase‐3.  Proc 
Natl Acad Sci USA. 2005; 102:16275–80.  
  https://doi.org/10.1073/pnas.0508105102 
40.  Vriend  J,  Reiter  RJ.  Melatonin  as  a  proteasome 
inhibitor. Is there any clinical evidence? Life Sci. 2014; 
115:8–14. https://doi.org/10.1016/j.lfs.2014.08.024 
41.  Janjetovic Z,  Jarrett  SG,  Lee EF, Duprey C, Reiter RJ, 
Slominski AT. Melatonin  and  its metabolites protect 
human  melanocytes  against  UVB‐induced  damage: 




Kim  EK.  Melatonin  reduces  endoplasmic  reticulum 
stress  and  corneal  dystrophy‐associated  TGFBIp 
through  activation  of  endoplasmic  reticulum‐
associated  protein  degradation.  J  Pineal  Res.  2017; 
63:e12426. https://doi.org/10.1111/jpi.12426 
43.  Digaleh  H,  Kiaei  M,  Khodagholi  F.  Nrf2  and  Nrf1 
signaling  and  ER  stress  crosstalk:  implication  for 
proteasomal  degradation  and  autophagy.  Cell  Mol 
Life Sci. 2013; 70:4681–94.  
  https://doi.org/10.1007/s00018‐013‐1409‐y 
44.  Kapeta  S,  Chondrogianni  N,  Gonos  ES.  Nuclear 




45.  Salminen  A,  Kauppinen  A,  Kaarniranta  K.  Emerging 
role  of  NF‐κB  signaling  in  the  induction  of 











cancer  stemness  through  the Nox/ROS/NF‐κB/STAT3 
signaling  cascade.  Cancer  Lett.  2016;  382:53–63. 
https://doi.org/10.1016/j.canlet.2016.08.023 
48.  Negi  G,  Kumar  A,  Sharma  SS. Melatonin modulates 
neuroinflammation  and  oxidative  stress  in 
experimental  diabetic  neuropathy:  effects  on NF‐κB 
and  Nrf2  cascades.  J  Pineal  Res.  2011;  50:124–31. 
https://doi.org/10.1111/j.1600‐079X.2010.00821.x 
49.  Gazdic M, Simovic Markovic B, Vucicevic L, Nikolic T, 
Djonov  V,  Arsenijevic  N,  Trajkovic  V,  Lukic  ML, 
Volarevic  V.  Mesenchymal  stem  cells  protect  from 
acute  liver  injury  by  attenuating  hepatotoxicity  of 
liver natural killer T  cells  in an  inducible nitric oxide 
synthase‐  and  indoleamine  2,3‐dioxygenase‐
dependent manner.  J  Tissue  Eng  Regen Med.  2018; 
12:e1173–85. https://doi.org/10.1002/term.2452 
50.  Huang  B,  Cheng  X, Wang  H,  Huang W,  la Ga  Hu  Z, 
Wang D, Zhang K, Zhang H, Xue Z, Da Y, Zhang N, Hu 
Y,  Yao  Z,  et  al.  Mesenchymal  stem  cells  and  their 
secreted  molecules  predominantly  ameliorate 
fulminant hepatic  failure and chronic  liver  fibrosis  in 
mice  respectively.  J  Transl  Med.  2016;  14:45. 
https://doi.org/10.1186/s12967‐016‐0792‐1 























































































































































































































































Score Pathological manifestations 
0 No abnormalities 
1-2 Liver structure remains intact，a few scattered hepatocyte necrosis，regional mild 
hepatocyte degeneration. 
3-4 Lobules of liver were disorder. Less than a third of the hepatic lobule was necrotic. The 
necrosis in the central area of the lobule is rare, and diffuse moderate hepatocyte 
degeneration. 
5-6 Most of the liver structures were destroyed. Moderate and severe necrotic. Lobular 







Grp78-F AGAAACTCCGGCGTGAGGTAGA   



























































































































































Gapdh -R GTAGCCCAGGATGCCTTTGAG 
























































shRNA Sequence (5'-3') 
ShNrf2-1-S GATCCGCAGCAGGACATTGAGCAATCAAGAGTTGCTCAATGTCCTGCTGCTTTTTTG 
ShNrf2-1-A AATTCAAAAAAGCAGCAGGACATTGAGCAACTCTTGATTGCTCAATGTCCTGCTGCG 
ShNrf2-2-S GATCCGTAAGAAGCCAGATATTAATCAAGAGTTAATATCTGGCTTCTTACTTTTTTG 
ShNrf2-2-A AATTCAAAAAAGTAAGAAGCCAGATATTAACTCTTGATTAATATCTGGCTTCTTACG 
Scrambled 
shRNA-S 
GATCCGATGAAATGGGTAAGTACATTCAAGAGATGTACTTACCCATTTCATCTTTTTT
G 
Scrambled 
shRNA-A 
AATTCAAAAAAGATGAAATGGGTAAGTACATCTCTTGAATGTACTTACCCATTTCAT
CG 
